Join Tomasz Piec, President of Supervisory Board, and Dominik Lipka, Director of Research and Development, Board Member and let’s discuss the potential opportunities of cooperation.
SyVento offers the development of encapsulated drugs for all kinds of pharmaceutically active ingredients based on various lipid-based formulations including Lipid Nanoparticles (LNP) for RNA.
The Congress brings together the leading companies developing RNA-based therapeutics and is a global platform for advancing scientific and commercial collaborations, as well as sharing the recent advances and challenges of the field.